DLL3 expression is significantly higher in glioblastoma, lower-grade glioma, skin cutaneous melanoma, tenosynovial giant-cell tumors, and uterine carcinosarcoma than in normal tissues, as shown in Figure 2. This evidence concerns the gene DLL3 and central nervous system cancer.